指南与共识泌尿生殖与妇科肿瘤放疗

ESTRO-ACROP 循证建议:前列腺癌外照射放疗联合雄激素剥夺治疗的应用

ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
指南 / 共识 · Radiother Oncol · 2023-02-20

欧洲放射肿瘤学会(ESTRO)放射肿瘤实践咨询委员会(ACROP)基于2000年1月至2022年5月的随机II、III期试验文献,提出前列腺癌原发及术后外照射放疗(EBRT)联合雄激素剥夺治疗(ADT)的循证建议。建议低危患者不加ADT,中危和高危患者分别推荐4-6个月和2-3年ADT;局部晚期患者推荐2-3年ADT,存在≥2个高危因素或cN1时推荐3年ADT加2年阿比特龙。术后pN0辅助EBRT不推荐ADT,pN1患者辅助EBRT联合长期ADT至少24-36个月。

要点

  • 低危前列腺癌患者不推荐额外ADT,中危和高危患者分别推荐4-6个月和2-3年ADT。
  • 局部晚期患者推荐2-3年ADT;有≥2个高危因素(cT3-4、ISUP分级≥4或PSA≥40 ng/ml)或cN1时推荐3年ADT加2年阿比特龙。
  • 术后pN0患者辅助EBRT不推荐ADT,pN1患者辅助EBRT联合长期ADT至少24-36个月。

核心结论

  • 这些ESTRO-ACROP建议基于证据,适用于前列腺癌外照射放疗联合ADT的最常见临床场景。

研究设计与样本

  • 在MEDLINE PubMed检索2000年1月至2022年5月发表的英文随机II期和III期试验,评估前列腺癌EBRT和ADT。
  • ACROP临床委员会由13名欧洲专家组成,讨论并分析ADT联合EBRT用于前列腺癌的证据。
  • 局限型前列腺癌按D'Amico等人分类分为低危、中危和高危。
  • 若某主题无II期或III期试验,则根据有限证据标注相应建议。

主要发现

  • 低危前列腺癌患者不推荐额外ADT,中危和高危患者分别推荐4-6个月和2-3年ADT。
  • 局部晚期前列腺癌患者推荐ADT 2-3年;存在≥2个高危因素(cT3-4、ISUP分级≥4或PSA≥40 ng/ml)或cN1时推荐ADT 3年加阿比特龙2年。
  • 术后pN0患者辅助EBRT不推荐ADT,pN1患者辅助EBRT联合长期ADT至少24-36个月。
  • 挽救性EBRT时,对生化持续但无转移证据的前列腺癌患者进行ADT。
  • pN0患者若进展风险高(PSA≥0.7 ng/ml且ISUP分级组≥4)且预期寿命超过十年,推荐长期ADT(24个月);pN0患者若风险较低(PSA<0.7 ng/ml且ISUP分级组4),推荐短期ADT(6个月)。

关键数值与推荐

  • 低危前列腺癌:不推荐额外ADT。
  • 中危前列腺癌:推荐ADT 4-6个月。
  • 高危前列腺癌:推荐ADT 2-3年。
  • 局部晚期前列腺癌:推荐ADT 2-3年;当≥2个高危因素(cT3-4、ISUP分级≥4或PSA≥40 ng/ml)或cN1存在时,推荐ADT 3年加阿比特龙2年。
  • 术后pN0患者辅助EBRT:不推荐ADT;pN1患者辅助EBRT联合长期ADT至少24-36个月。

临床怎么用

  • 根据D'Amico分类确定局限型前列腺癌风险分组后,低危不加ADT,中危用4-6个月ADT,高危用2-3年ADT。
  • 局部晚期患者给2-3年ADT;若≥2个高危因素或cN1,则用3年ADT加2年阿比特龙。
  • 术后pN0辅助EBRT不加ADT;pN1辅助EBRT联合长期ADT至少24-36个月。
  • 挽救性EBRT时,生化持续无转移者进行ADT;pN0高风险者用24个月ADT,低风险者用6个月ADT。
  • 超低分次EBRT或影像学局部复发/淋巴结复发者应参加评估额外ADT的临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: There is no consensus concerning the appropriate use of androgen deprivation therapy (ADT) during primary and postoperative external-beam radiotherapy (EBRT) in the management of prostate cancer (PCa). Thus, the European Society for Radiotherapy and Oncology (ESTRO) Advisory Committee for Radiation Oncology Practice (ACROP) guidelines seeks to present current recommendations for the clinical use of ADT in the various indications of EBRT. MATERIAL AND METHODS: A literature search was conducted in MEDLINE PubMed that evaluated EBRT and ADT in prostate cancer. The search focused on randomized, Phase II and III trials published in English from January 2000 to May 2022. In case topics were addressed in the absence of Phase II or III trials, recommendations were labelled accordingly based on the limited body of evidence. Localized PCa was classified according to D'Amico et al. classification in low-, intermediate and high risk PCa. The ACROP clinical committee identified 13 European experts who discussed and analyzed the body of evidence concerning the use of ADT with EBRT for prostate cancer. RESULTS: Key issues were identified and are discussed: It was concluded that no additional ADT is recommended for low-risk prostate cancer patients, whereas for intermediate- and high-risk patients four to six months and two to three years of ADT are recommended. Likewise, patients with locally advanced prostate cancer are recommended to receive ADT for two to three years and when ≥ 2 high-risk factors (cT3-4, ISUP grade ≥ 4 or PSA ≥ 40 ng/ml) or cN1 is present ADT for three years plus additional Abiraterone for two years is recommended. For postoperative patients no ADT is recommended for adjuvant EBRT in pN0 patients whereas for pN1 patients adjuvant EBRT with long-term ADT is performed for at least 24 to 36 months. In the setting of salvage EBRT ADT is performed in biochemically persistent PCa patients with no evidence of metastatic disease. Long-term ADT (24 months) is recommended in pN0 patients with high risk of further progression (PSA ≥ 0.7 ng/ml and ISUP grade group ≥ 4) and a life expectancy of over ten years, whereas short-term ADT (6 months) is recommended in pN0 patients with lower risk profile (PSA < 0.7 ng/ml and ISUP grade group 4). Patients considered for ultra-hypofractionated EBRT as well as patients with image based local recurrence within the prostatic fossa or lymph node recurrence should participate in appropriate clinical trials evaluating the role of additional ADT. CONCLUSION: These ESTRO-ACROP recommendations are evidence-based and relevant to the use of ADT in combination with EBRT in PCa for the most common clinical settings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Schmidt-Hegemann NS, Zamboglou C, Mason M, et al. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiother Oncol. 2023. PMID: 36813168. doi:10.1016/j.radonc.2023.109544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。